Metraipolis › archive › dc_045b8e3ee596

Cotargeting DNA topoisomerase II enhances efficacy of RAS-targeted therapy in KRAS-mutant cancer models — Europe PMC PMID:41697749

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41697749
DOI
10.1172/jci197192
License (as archived)
solo-consultazione
Archived
2026-11-05T18:04:44.039Z
SHA-256 of the archived text
cb686987d2f302ae2114612a15c824d287352f8a194ca5728576cbe4aa9880b8
Stable URL of this page
https://metraipolis.com/documento/dc_045b8e3ee596

How to cite

Cotargeting DNA topoisomerase II enhances efficacy of RAS-targeted therapy in KRAS-mutant cancer models — Europe PMC PMID:41697749 — Europe PMC (en), https://europepmc.org/article/MED/41697749 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_045b8e3ee596 (Metraipolis archive dc_045b8e3ee596, sha256 cb686987d2f302ae2114612a15c824d287352f8a194ca5728576cbe4aa9880b8)
BibTeX
@misc{dc045b8e3ee596,
  title = {Cotargeting DNA topoisomerase II enhances efficacy of RAS-targeted therapy in KRAS-mutant cancer models — Europe PMC PMID:41697749},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41697749},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_045b8e3ee596; sha256 cb686987d2f302ae2114612a15c824d287352f8a194ca5728576cbe4aa9880b8},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41697749. Agents can read the archived copy with the MCP tool read_document.